Other genes such as KL, MNX1, HMCN1 and ADCY10 suggest that anoikis resistance is not restricted to survival pathways but also extends to metabolic and proliferative mechanisms that drive both tumour aggressiveness and treatment resistance [42–45]. This evidence concerns the gene HMCN1 and neoplasm.